About 40 percent of patients with lower-risk myelodysplastic syndromes (LR-MDS) die of MDS within five years, according to a study published online Nov. 6 in the British Journal of Haematology.
Nov 23, 2022
0
2
For newly diagnosed chronic-phase chronic myeloid leukemia (CML) patients, adherence to guideline-based quality indicators is low, according to a study published online Nov. 11 in Leukemia & Lymphoma.
Nov 23, 2022
0
2
The COVID-19 pandemic has led to an explosion of clinical research resulting in the development of a variety of vaccines and treatments, although the efficacy of some remains controversial. Now, researchers from Japan report ...
Nov 22, 2022
0
27
A new research paper was published in Oncotarget entitled, "Mutation analysis performed on tumor biopsies from patients with newly-diagnosed germinal center aggressive B cell lymphomas."
Nov 17, 2022
0
2
The U.S. Food and Drug Administration approved the combination of tremelimumab (Imjudo) plus durvalumab (Imfinzi) and platinum-based chemotherapy for adult patients with metastatic non-small cell lung cancer with no sensitizing ...
Nov 16, 2022
0
47
A Texas cardiac subspecialty hospital with seven years of experience with extracorporeal membrane oxygenation (ECMO) changed its treatment paradigm during the COVID-19 pandemic, finding that progressive mobility and a more ...
Nov 15, 2022
0
4
New research from University of Alabama at Birmingham researchers is shedding light on racial disparities in breast cancer mortality in women who live in economically deprived neighborhoods.
Nov 8, 2022
0
57
Although racial disparities in survival after in-hospital cardiac arrest among Black and white people are known, both groups had similar chances of receiving an intensive care unit (ICU) evaluation before a cardiac arrest. ...
Oct 31, 2022
0
4
Among children who experienced in-hospital cardiac arrest in the last 20 years, survival rates have increased significantly. Greater improvements have been seen among children who had recent cardiac surgery and cardiac arrest, ...
Oct 31, 2022
0
0
Giving the combination of immune checkpoint inhibitors relatlimab and nivolumab to patients with stage III melanoma before surgery was safe and completely cleared all viable tumor in 57% of patients in a Phase II study, researchers ...
Oct 26, 2022
0
55
